Alector soars on Genentech deal for experimental Parkinson's drug
** Shares of drug maker Alector ALEC.O surge 44.20% to $2.61 premarket
** Co enters global licensing deal with Genentech for AL050, ALEC's experimental drug for Parkinson's disease
** ALEC grants Genentech exclusive global rights to develop and commercialize AL050
** The deal brings $100 million upfront and is eligible for up to $1.17 billion in milestone payments into 2029 - ALEC
** Co retains ownership of its ABC platform, its technology platform for developing neurodegenerative disease therapies, and full rights for pipeline use
** As of last close, ALEC up 16.03%